BRAF and melanoma: The pivotal COMBI‐AD trial demonstrated the efficacy of 12 months of adjuvant dabrafenib plus trametinib (BRAF/MEK inhibitors) compared to placebo in patients with resected Stage III melanoma harboring BRAF V600E/K mutations [5].